论文部分内容阅读
[目的]探讨EB病毒(EBV)与鼻咽癌(NPC)2008分期的相关性;比较EBV IgA抗体滴度与EBV DNA拷贝数在NPC诊断与疗效评价中的差异。[方法]将初诊为NPC的患者98例,在放化疗前予以TNM分期;在放化疗前、后分别监测血清EBV抗体滴度与全血EBV DNA拷贝数。在放化疗后2个月,复查鼻咽部磁共振及全身检查后评价疗效。[结果]治疗前,血清EBVIgA抗体滴度阳性患者28例,全血EBVDNA拷贝数阳性42例。EBV IgA抗体滴度及全血EBV DNA拷贝数在不同TNM分期上差异均无统计学意义(P=0.189,P=0.074)。全血EBV DNA拷贝数在Ⅲ期与Ⅱ期、Ⅲ期与Ⅳa期间比较,差异均具有统计学意义(P=0.024,P=0.022)。放疗后,全血EBV DNA拷贝数转阴率高;但在提示转移或复发方面,EBV IgA抗体与EBV DNA比较二者差异无统计学意义(P=0.095)。[结论]血清EBV IgA抗体与NPC2008分期无相关性。全血EBV DNA拷贝数与NPC2008分期具有一定相关性。全血EBV DNA拷贝数转阴率高,优于EBVIgA抗体,在一定程度上能有效评价治疗疗效及监测病情变化。
[Objective] To explore the correlation between Epstein-Barr virus (EBV) and nasopharyngeal carcinoma (NPC) 2008 staging. To compare the difference between EBV IgA antibody titer and EBV DNA copy number in the diagnosis and evaluation of NPC. [Methods] 98 patients newly diagnosed with NPC were treated with TNM before radiotherapy and chemotherapy. The serum EBV antibody titers and whole blood EBV DNA copy number were monitored before and after radiotherapy and chemotherapy. 2 months after radiotherapy and chemotherapy, review of nasopharyngeal magnetic resonance and systemic examination after evaluation of efficacy. [Results] Before treatment, 28 cases were positive for EBV IgA antibody titer and 42 cases were positive for EBV DNA copy number. EBV IgA antibody titer and whole blood EBV DNA copy number in different TNM staging differences were not statistically significant (P = 0.189, P = 0.074). The EBV DNA copy number of whole blood in stage Ⅲ and Ⅱ, Ⅲ and Ⅳa, the differences were statistically significant (P = 0.024, P = 0.022). After radiotherapy, the EBV DNA copy number in whole blood turned negative, but there was no significant difference between EBV IgA antibody and EBV DNA in suggestive metastasis or recurrence (P = 0.095). [Conclusion] There is no correlation between serum EBV IgA antibody and NPC2008 staging. Whole blood EBV DNA copy number and NPC2008 staging have some relevance. EBV DNA copy number of whole blood, the negative rate is higher than the EBVIgA antibody, to a certain extent, can effectively evaluate the efficacy of treatment and monitoring of disease changes.